Sign in
Taking peoplePhase 4

Oral Switch in Bloodstream Infections in Immunocompromised Children

Key facts

Who runs it
Copenhagen University Hospital, Rigshospitalet
Where
Denmark4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
114 people, planned
Started
9 Nov 2026
Expected to end
1 Feb 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Oral antibiotic therapy
  • Standard IV antibiotic therapy
Record updated
10 November 2026

Who can take part

Age
4 weeks to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 4 weeks to 17 years
  • Underlying medical condition associated with immunosuppression and/or presence of a central venous catheter
  • Positive blood culture with a high-pathogenic bacterium. Eligible pathogens include Gram-negative bacteria and Gram-positive bacteria such as Staphylococcus aureus, Streptococcus mitis, Streptococcus pneumoniae, β-haemolytic streptococci, and Enterococcus spp., for which standard treatment is at least 7 days of intravenous antibiotics
  • Clinical stability, defined as: (a) respiratory and hemodynamically stable, without need for oxygen, IV fluid therapy or inotropic support; and (b) well-appearing with signs of clinical improvement (e.g., improved physical activity), as judged by the investigator
  • Afebrile for 24 hours
  • Tolerating oral fluids and diet and considered to have adequate gastrointestinal absorption for age, as judged by the investigator
  • Within the randomization window: i) As soon as possible after eligibility is confirmed and ii) within 3-6 days of effective IV antibiotics (72-144 hours) including the duration of the last IV dose
  • Informed consent obtained from a parent or guardian, and from the patient if of appropriate age; Polymicrobial episodes are allowed

Who cannot take part

  • Within the follow-up period (≤6 weeks) of a previous randomization for another pathogen covered by the antibiotic indicated for the index episode
  • Complicated infections; Tunnel infection associated with a CVC, unless the CVC is removed; Suspected CNS infection; Other focal infections requiring prolonged antibiotic therapy beyond the treatment of bacteremia, e.g., deep-seated abscess or other deep-seated infections, bone or joint infections, and endocarditis
  • Planned to receive prophylactic antibiotic therapy covering the pathogen after completion of treatment for the index infection
  • Blood culture with Pseudomonas aeruginosa, Neisseria meningitidis, or low-pathogenic possible contaminants of uncertain clinical relevance, including coagulase-negative staphylococci, Micrococcus spp., Corynebacterium spp., Cutibacterium acnes, and Bacillus spp
  • Clinically significant mucositis (e.g. stomatitis CTCAE (Common Terminology Criteria for Adverse Events) grade ≥3, defined as severe pain interfering with oral intake)
  • No suitable oral antibiotic available (e.g., due to antimicrobial resistance or contraindications)
  • A decision to discontinue life-prolonging treatment has been made, with a life expectancy of less than 6 weeks, as assessed by the treating physician

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This nationwide, multicenter, randomized non-inferiority trial aims to determine whether an switch to oral antibiotic therapy (experimental arm) is non-inferior to standard intravenous antibiotic therapy (control arm) with respect to recurrence in children and adolescents with uncomplicated bloodstream infections, who are immunocompromised or have a central venous catheter.

The 2 groups in the trial

  • Early Oral SwitchTreatment being tested

    Treatment: Oral antibiotic therapy

  • Standard Intravenous TherapyExisting treatment, for comparison

    Treatment: Standard IV antibiotic therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Oral Switch Versus Standard Intravenous Antibiotics in Children and Adolescents Who Are Immunocompromised and/or a Central Venous Catheter and Uncomplicated Bloodstream Infections: a Nationwide Randomised Controlled Non-inferiority Trial
Record updated
10 November 2026